相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms
Rhonda M. Cooper-DeHoff et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study
Iveta Mercep et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat
Brian A. Willis et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
Zhi-Ping Jiang et al.
PHARMACOGENOMICS (2017)
Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers
Tae-Eun Kim et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer
Houshiyar Ghafouri et al.
TUMOR BIOLOGY (2016)
No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects
J. Huguet et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Effects of Polymorphisms in NR1H4, NR1I2, SLCO1B1, and ABCG2 on the Pharmacokinetics of Rosuvastatin in Healthy Chinese Volunteers
Mei Liu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States
Bruce K. Birmingham et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?
Bruce K. Birmingham et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Marked Alteration of Rosuvastatin Pharmacokinetics in Healthy Chinese with ABCG2 34G>A and 421C>A Homozygote or Compound Heterozygote
Zirui Wan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care
Marianne K. DeGorter et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2013)
Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients
Hon-Kit Lee et al.
PHARMACOGENOMICS (2013)
HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants
Lucas D. Ward et al.
NUCLEIC ACIDS RESEARCH (2012)
ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin
B. Tomlinson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
J. E. Keskitalo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin
Satoshi Kitamura et al.
DRUG METABOLISM AND DISPOSITION (2008)
Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales
Julian P. T. Higgins et al.
STATISTICS IN MEDICINE (2008)
The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2)
L. J. A. Hardwick et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
Role of BCRP 421C>A polymorphism on rosuvastatin pharynacokinetics in healthy Chinese males
Wei Zhang et al.
CLINICA CHIMICA ACTA (2006)
Drug and bile acid transporters in rosuvastatin hepatic uptake: Function, expression, and pharmacogenetics
Richard H. Ho et al.
GASTROENTEROLOGY (2006)
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
E Lee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Single nucleotide polymorphisms modify the transporter activity of ABCG2
K Morisaki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2
S Mizuarai et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Functional analysis of SNPs variants of BCRP/ABCG2
C Kondo et al.
PHARMACEUTICAL RESEARCH (2004)
Benefit-risk assessment of rosuvastatin 10 to 40 milligrams
HB Brewer
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat
K Nezasa et al.
XENOBIOTICA (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
分享论文
